Synthesis of beta-hydroxyisovalerate and methods of use
The biological production of beta-hydroxyisovalerate (βHIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active βHIV metabolic pathway for the production of βHIV. Alternatively, the non-natural enzyme can be a βHIV synthase used to produce βHIV in a cell-free environment. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
1. A non-natural enzyme capable of producing beta-hydroxyisovalerate (βHIV), the non-natural enzyme comprising one or more amino acid modifications or mutations relative to a corresponding enzyme lacking the substitutions, wherein the non-natural enzyme comprises one or more modifications or mutations at substrate-specificity positions corresponding to amino acids selected from V212, L224, Q251 and F371, of any of SEQ ID NO: 1 or SEQ ID NO: 6, and wherein the non-natural enzyme is modified or mutated to provide more beta-hydroxyisovalerate (βHIV) synthase activity than a corresponding enzyme with the same amino acid sequence lacking the one or more amino acid modifications or mutations.
2. The non-natural enzyme of claim 1 , wherein the non-natural enzyme is at least 65% identical to at least one polypeptide selected from the group consisting of SEQ ID NOS: 1-148.
3. The non-natural enzyme of claim 1 , wherein the non-natural enzyme is at least 65% identical to at least one polypeptide selected from the group consisting of SEQ ID NOS: 1-6.
4. The non-natural enzyme of claim 1 , wherein the non-natural enzyme comprises two or more modifications or mutations at substrate-specificity positions corresponding to amino acids selected from V212, L224, Q251 and F371, of SEQ ID NO: 1 or SEQ ID NO: 6.
5. The non-natural enzyme of claim 4 , wherein the two or more modifications or mutations comprises altering two or more of the substrate-specificity positions corresponding to amino acids selected from the group consisting of Q251 and F371 or V212 and L224, of SEQ ID NO: 1 or SEQ ID NO: 6.
6. The non-natural enzyme of claim 1 , wherein the one or more modifications or mutations comprises one or more substrate-specificity position modifications or mutations selected from the group of methionine at position 224, proline at position 251, and leucine at position 212, of SEQ ID NO: 1 or SEQ ID NO: 6.
7. A modified microorganism expressing the non-natural enzyme of claim 1 .
8. The modified microorganism of claim 7 , wherein the modified microorganism expresses or overexpresses at least one gene encoding for βHIV synthase having at least 65% identity to the group consisting of SEQ ID NOS: 1-148.
9. The modified microorganism of claim 8 , wherein the modified microorganism comprises a βHIV metabolic pathway in the cytosol.
10. The modified microorganism of claim 7 , wherein the modified microorganism comprises an active βHIV metabolic pathway from pyruvate to βHIV comprising (i) pyruvate into acetolactate, (ii) acetolactate into 2,3-dihydroxyisovalerate, (iii) 2,3-dihydroxyisovalerate into α-ketoisovalerate, (iv) α-ketoisovalerate into α-isopropylmalate, (v) α-isopropylmalate into β-isopropylmalate, (vi) β-isopropylmalate into α-ketoisocaproate, and (vii) α-ketoisocaproate into βHIV.
11. The modified microorganism of claim 7 , wherein the modified microorganism comprises an active βHIV metabolic pathway from pyruvate to βHIV comprising (i) pyruvate into acetolactate, (ii) acetolactate into 2,3-dihydroxyisovalerate, (iii) 2,3-dihydroxyisovalerate into α-ketoisovalerate, (iv) α-ketoisovalerate into 2-isopropylmalate, (v) 2-isopropylmalate into 2-isopropylmaleate, (vi) 2-isopropylmaleate into 3-isopropylmalate, (vii) 3-isopropylmalate into 2-isopropyl-3-oxosuccinate, (viii) 2-isopropyl-3-oxosuccinate into α-ketoisocaproate, and (ix) α-ketoisocaproate into βHIV.
12. The modified microorganism of claim 7 , wherein the modified microorganism is a yeast or a bacteria.
13. The modified microorganism of claim 7 , wherein the modified microorganism is a yeast selected from the group consisting of Saccharomyces, Kluyveromyces, Pichia, Issatchenkia, Hansenula , or Candida.
14. The modified microorganism of claim 7 , wherein the modified microorganism is a prokaryotic bacterium, wherein the prokaryotic bacterium is selected from a Gram-positive bacterium or a Gram-negative bacterium, the Gram-positive bacterium comprising Corynebacterium, Lactobacillus, Lactococcus or Bacillus , and the Gram-negative bacteria comprising Escherichia or Pseudomonas.
15. A method of producing beta-hydroxyisovalerate (βHIV) using a non-natural enzyme expressed in a microorganism, the method comprising:
providing a non-natural enzyme expressed in a microorganism, the non-natural enzyme comprising one or more amino acid modifications or mutations relative to a corresponding enzyme lacking the substitutions, wherein the non-natural enzyme comprises one or more modifications or mutations at substrate-specificity positions corresponding to amino acids selected from V212, L224, Q251 and F371, of any of SEQ ID NO: 1 or SEQ ID NO: 6, and wherein the non-natural enzyme is modified or mutated to provide more beta-hydroxyisovalerate synthase activity than a corresponding enzyme with the same amino acid sequence lacking the one or more amino acid modifications or mutations;
cultivating the microorganism in a culture containing a feedstock of a carbon source until a recoverable quantity of βHIV is produced; and
recovering the recoverable quantity of produced βHIV.
16. The method of claim 15 , further comprising purifying the recoverable quantity of βHIV.
17. The method of claim 15 , wherein the microorganism comprises a βHIV metabolic pathway cultivated in the culture medium containing a feedstock of a carbon source to produce βHIV.
18. The method of claim 17 , wherein the carbon source is selected from the group consisting of glucose, xylose, arabinose, sucrose, fructose, lactose, glycerol, and mixtures thereof.
19. The method of claim 15 , wherein the microorganism cultivated in the culture produces βHIV at a yield of at least about 0.1 percent up to 100 percent of theoretical yield.
20. The method of claim 15 , wherein the microorganism comprises a βHIV metabolic pathway in contact with a carbon source in a fermenter to produce βHIV, wherein the fermenter introduces sufficient nutrients such that a final βHIV concentration in a fermentation broth is greater than about 10 mg/L.